Thymosin Alpha-1 Injection: How It Is Given in Studies

In plain English

In essentially every study, Thymosin Alpha-1 injection means one thing: a small shot of the peptide given under the skin — a subcutaneous injection, the same shallow kind used for insulin. It is not given as a pill (the peptide would be broken apart by digestion) and not, in the clinical record, through a vein. The peptide comes as a freeze-dried (lyophilized) powder that has to be mixed with sterile liquid before use. Because the body clears it from the blood within a day, trials gave it on a repeating schedule rather than once. The most-studied long-term schedule is a small twice-weekly shot; sepsis trials gave it more often for about a week. The most common thing people notice from the injection itself is a little redness or stinging at the spot. Everything below reports how the shot was used in research — not how anyone should use it.

Why subcutaneous, and why repeated

The subcutaneous route is the clinical route for this peptide in essentially all trials ^[4]. The reason is partly the molecule: a short, highly acidic peptide cleared by aminopeptidases would not survive oral digestion, and its roughly 2-hour plasma half-life means a single dose clears within about a day ^[8]. Yet the immunological effect outlasts that brief plasma window, which is why intermittent injection works — the schedule chases the biology, not the blood level. Subcutaneous delivery also routes the peptide efficiently to immune tissue: a mouse biodistribution study found high uptake in thymus, spleen, and lungs after dosing ^[10].

The injection regimens, by population

Reported as study-attributed research data — amounts given to defined populations by the subcutaneous route, not instructions:

• Chronic hepatitis B/C — 1.6 mg subcutaneous twice weekly, the standard chronic regimen ^[9].
• Sepsis (ETASS, TESTS) — 1.6 mg subcutaneous every 12 hours for five to seven days in adult ICU patients ^[2][3].
• Severe COVID-19 cohorts — 1.6 mg subcutaneous daily ^[6].
• Reported range — single subcutaneous doses of 0.8-6.4 mg; multiple-dose regimens 1.6-16 mg over five to seven days ^[4].

Each figure belongs to its studied population; none generalizes to unstudied or self-directed use.

What follows the injection

The injection is generally well tolerated. Across large post-marketing surveillance of hundreds of thousands of treated patients, the dominant adverse events were mild local reactions — redness, itching, burning, or discomfort at the injection site — with occasional transient flu-like symptoms and no documented organ toxicity at studied doses ^[15]. The Thymosin Alpha-1 side effects page covers the full reported safety picture; the short version is that the needle, not the molecule, accounts for most of what people report.